Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence

(MedPage Today) -- Why is donanemab, an investigational anti-amyloid agent for early Alzheimer's disease, facing an approval delay? (The Guardian) Early use of erenumab (Aimovig) showed sustained efficacy compared with oral migraine preventives...
Source: MedPage Today Neurology - Category: Neurology Source Type: news